The Cheshier lab focuses on enhanced immunotherapy treatment of malignant pediatric brain tumors and understanding the treatment’s molecular mechanism. Some of the deadliest tumors we target are medulloblastoma (MB) and pediatric glioblastoma multiforme (pGBM). Both are malignant high-grade brain tumors, often fatal. Medulloblastoma is the most common malignant brain tumor in children; it accounts for about 20% of all pediatric brain. Glioblastoma accounts for 3–15% of primary central nervous system tumors in children.